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Abstract 
Toll-like receptor 4 (TLR4) recognizes various endogenous and microbial ligands and is an 
essential part in the innate immune system. TLR4 signaling initiates transcription factor NF-κB and 
production of proinflammatory cytokines. TLR4 contributes to the development or progression of 
various diseases including stroke, neuropathic pain, multiple sclerosis, rheumatoid arthritis and 
cancer, and better therapeutics are currently sought for these conditions. In this study, a library of 
140 000 compounds was virtually screened and a resulting hit-list of 1000 compounds was tested 
using a cellular reporter system. The topoisomerase II inhibitor mitoxantrone and its analogues 
pixantrone and mitoxantrone (2-hydroxyethyl)piperazine were identified as inhibitors of TLR4 and 
NF-κB activation. Mitoxantrone was shown to bind directly to the TLR4, and pixantrone and 
mitoxantrone (2-hydroxyethyl)piperazine were shown to inhibit the production of proinflammatory 
cytokines such as tumor necrosis factor alpha (TNFα) in primary microglia. The inhibitory effect on 
NF-κB activation or on TNFα production was not mediated through cytotoxity at ≤ 1 µM 
concentration, as assessed by ATP counts for mitoxantrone, pixantrone and mitoxantrone (2-
hydroxyethyl)piperazine treated cells. This study thus identifies a new mechanism of action for 
mitoxantrone, pixantrone, and mitoxantrone (2-hydroxyethyl)piperazine through the TLR4. 
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1 Introduction 
Toll-like receptors (TLRs) belong to the family of pattern recognition receptors (Jeannin et al., 
2008) and are mediators of innate immune system activation. Thirteen mammalian TLRs have been 
identified, and ten of them are functional in human. TLRs recognize various ligands (Janssens and 
Beyaert, 2003; Kanzler et al., 2007). These ligands are for a large part of microbial origin, referred 
to as pathogen-associated molecular patterns (PAMPs), of which, lipopolysaccharide (LPS) from 
Gram-negative bacteria is a prominent example. In addition, TLRs recognize various endogenous 
ligands called damage-associated molecular patterns (DAMPs) that include such as heat-shock 
proteins, β-defensins and high mobility group box 1 (HMGB1). 
TLR4 has received considerable attention in recent years, mostly because of its therapeutic 
potential. TLR4 is widely expressed in periphery, but also in CNS, mostly in astrocytes and 
microglia (Vaure and Liu, 2014), and it is involved in the development/maintenance of chronic pain 
and neuroinflammation (Kuang et al., 2012; Nicotra et al., 2012; Tanga et al., 2005), multiple 
sclerosis (MS) (Miranda-Hernandez and Baxter, 2013), rheumatoid arthritis (Maciejewska 
Rodrigues et al., 2009), cancer (Oblak and Jerala, 2011), and tissue damages after stroke (Hyakkoku 
et al., 2010; Tang et al., 2007). All these conditions are in high need for better therapeutic 
compounds. As an example, chronic pain is affecting up to 1.5 billion of people and is responsible 
for one of the highest expenses in health care systems worldwide (Jacobs, 2005). It results from 
complex pathological processes, of which neuronal and non-neuronal cells - such as microglia and 
astrocytes - are involved. A significant role of the inflammatory system has been identified in the 
development and maintenance of chronic pain including neuropathic pain (Grace et al., 2011; 
Meller et al., 1994; Milligan and Watkins, 2009; Watkins et al., 1997) and opioid-induced 
hyperalgesia and tolerance (Mattioli et al., 2014). More specifically, TLR4-mediated microglial 
activation has been shown to be one of the initiators in the development of neuropathic and chronic 
pain (Kuang et al., 2012; Nicotra et al., 2012; Tanga et al., 2005). Conversely, reduced production 
of proinflammatory cytokines, seen in animal models lacking TLR4 or achieved via blocking TLR4 
with small molecules, has a reducing effect on inflammatory and neuropathic pain (Liu et al., 2012; 
Sommer et al., 1999; Sorge et al., 2011; Wu et al., 2010, 2015; Zhou et al., 2018). Another example, 
MS, is an autoimmune disease and one of the most common neurologic disorder. Toll-like receptors 
in the innate immune system are involved in the development of autoimmune inflammation 
(O’Brien et al., 2008). TLR4s and endogenous ligand HMGB1 are highly expressed in MS patients 
(Andersson et al., 2008), but association between the receptor and disease has remained unclear 
(Kroner et al., 2005; Reindl et al., 2003). 
TLRs act as units by forming homo- or heteromers, and crystal structures have been characterized 
for most of the TLRs. TLRs share the same protein fold through species from invertebrates to 
vertebrates (Rock et al., 1998). Leucine-rich repeats form a horseshoe-like extracellular domain, 
which participates in ligand binding and recognition (Akira et al., 2006). The extracellular domain 
is joined together with an intracellular toll/interleukin-1 receptor homology domain (TIR-domain) 
(Kawai and Akira, 2009), which activates signaling pathways. The extracellular domain and TIR-
domain are connected by a single alpha-helical transmembrane domain. 
Upon activation TLR4 forms a complex with the co-ligand and helper protein myeloid 
differentiation factor 2 (MD-2, also referred to as lymphocyte antigen 96). The dimerization of this 
TLR4 unit causes activation of the signaling pathway by bringing together intracellular TIR-
domains. This complex further recruits cytoplasmic adaptor proteins, such as myeloid 
differentiation primary response 88 (MyD88), TIR domain-containing adaptor protein (TIRAP) and 
TIR-domain-containing adapter-inducing interferon-β (TRIF), leading to activation of various 
protein kinases and transcription factors (Akira et al., 2003). Downstream of the TLR4 signaling 
         
cascade (Lu et al., 2008), the transcription factor NF-κB is one of the most important modulators of 
the activation of the innate immune system. NF-κB is in charge of the production of various 
secreted proteins called proinflammatory cytokines, including TNFα and interleukin 1β (IL-1β) that 
are essential for an effective immune response (Baeuerle and Henkel, 1994; Peri and Piazza, 2012).  
A three-dimensional structure of a complex of human TLR4, MD-2 and LPS has been solved by X-
ray crystallography (PDB code: 3FXI) (Park et al., 2009). The helper protein MD-2 consists of β-
sheets that are surrounding a hydrophobic pocket for ligand binding. LPS binds to this pocket with 
its lipid chains, and causes the formation of the TLR4 and MD-2 complex. MD-2 undergoes 
conformational changes upon dimerization with TLR4, having one of its loops, the F126 loop, 
forming polar interactions with TLR4. LPS forms a direct bridge between TLR4 and MD-2. LPS 
has six lipid chains, of which five bind into the hydrophobic pocket of MD-2 and one forms a 
hydrophobic interaction with conserved phenylalanines (Phe-440, Phe-463) of TLR4. 
Only few high-affinity small molecule ligands of TLR4 had been reported when we started the 
study in 2013. The TLR4-specific small molecule antagonist ethyl (6R)-6-[(2-chloro-4-
fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate (TAK-242) (Figure 1) advanced to clinical 
trials for the treatment of sepsis, but it failed to show therapeutic effect (Rice et al., 2010). TAK-
242 has been suggested to bind covalently to the intracellular domain of TLR4, more specifically to 
Cys-747 (Matsunaga et al., 2011; Takashima et al., 2009), and to trap the receptor in an inactive 
state by interfering with protein-protein interactions of adaptor proteins. In addition,  β-amino 
alcohol derivatives (Figure 1) (Bevan et al., 2010; Chavez et al., 2011) have been reported to target 
and inhibit TLR4 by binding to MD-2 loop site and disrupting the formation of the TLR4 and MD-2 
complex. β-amino alcohol derivatives alone did not have analgesic effect, but they potentiated the 
analgesic effect of morphine by inhibiting morphine-induced TLR4 activation (Bevan et al., 2010). 
Some lipid mimetics have been found to have an inhibitory effect on TLR4 (Meng et al., 2010). 
These compounds aimed at mimicking the glycolipid part of LPS to maintain the selectivity and 
potency towards TLR4. However, mimetics often come with the disadvantage of large size that 
limits their use as drugs. Lipid mimetics are commonly known to bind to the LPS-binding site in 
TLR4 and/or MD-2 (Ohto et al., 2012; Scior et al., 2013). The TLR4 specific lipid mimetic 
antagonist, [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-
methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-
yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate (eritoran) (Mullarkey 
et al., 2002), reached clinical trials in severe sepsis, but did not show therapeutic effect (Opal et al., 
2013). 
In this study, a virtual screen on a library of 140 000 compounds was conducted, a hit list of 1000 
compounds was tested by experimental screening using a cellular reporter assay, and the hits from 
the experimental screening were further validated. After validation of the hits from primary 
experimental screen, one positive hit was found, mitoxantrone (1,4-dihydroxy-5,8-bis[2-(2-
hydroxyethylamino)ethylamino]anthracene-9,10-dione) (Figure 1), which was further investigated 
more in details together with two commercially available derivatives, mitoxantrone (2-
hydroxyethyl)piperazine (8,11-dihydroxy-4-(2-hydroxyethyl)-6-[2-(2-
hydroxyethylamino)ethylamino]-2,3-dihydro-1H-naphtho[3,2-f]quinoxaline-7,12-dione) (Figure 1). 
The biological effect of the compounds through TNFα production was assessed in primary 
microglia from mouse. Furthermore, a direct binding mechanism to the target receptor was 
demonstrated using [
3
H]mitoxantrone on TLR4 expressing membrane fractions from the HEK-
Blue™-hTLR4 cell line.  
         
2 Materials and Methods 
Virtual screening – The crystal structure of TLR4 with the co-crystallized ligand LPS was used 
(PDB code: 3FXI (Park et al., 2009)). As the starting point to identify novel antagonists for TLR4, a 
library of ca. 140 000 compounds (https://www.fimm.fi/en/services/technology-
centre/htb/equipment-and-libraries/chemical-libraries, October 2015) was screened virtually. The 
library includes for example a subset of approved drug molecules (ca. 640 compounds), natural 
products (ca. 1 000), and a set of diverse drug-like compounds (ca. 50 000). The library was 
converted into 3D format using Maestro (LigPrep) and Canvas by Schrödinger (“Schrödinger 
Release 2015-3: Maestro, Version 10.3, Schrödinger, LLC, New York, NY.,” 2015) at pH 7.4 with 
standard parameters. The library preparation allows creation of ionic and tautomeric forms. For 
compounds of undefined chirality, a single enantiomer was randomly kept in order to avoid creating 
a representation bias and in the same time to limit the size of the prepared library for docking. Upon 
analysis of the hit lists, duplicates were automatically removed, as well as compounds with 
substructures prone to chemical reactivity and pan-assay interference (Baell and Nissink, 2018; 
Rishton, 1997). 
All virtual screens were hampered by the scarcity of active compounds to be used as references. 
Therefore, a relatively large (1000 compounds) hit-list was built to be experimentally tested. Five 
independent screens were conducted, each leading to a hit list of 200 compounds: one by similarity 
search, two by pharmacophore, and two by docking. All of the methods produced ranked lists, 
which were filled up to 200 compounds, if the initial compounds were removed e.g. because of the 
presence in duplicate lists or physical unavailability. 
For the ligand-based similarity search, a known racemic β-amino alcohol-derived TLR4 antagonist, 
1-[[[1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]methyl](methyl)amino]-3-(4-
chlorophenoxy)propan-2-ol, was used (Bevan et al., 2010) as a starting point (Figure 1). The search 
was based on molecular Fingerprints (Willett, 2003) ranked using a Tanimoto similarity coefficient 
of Discovery Studio v4.5 (BIOvIA, 2015: Dassault Systèmes, San Diego, CA, USA). 
Pharmacophore modeling was also conducted using DiscoveryStudio v4.5. For the pharmacophore-
based and docking-based screens, small-molecule antagonists were hypothesized either compete for 
the LPS binding site or for the MD-2 loop binding site in TLR4; leading to four independent hit 
lists. Pharmacophoric features were selected manually using Maestro 10.3 [Schrödinger] and PyMol 
1.7.0.0 (PyMOL 1.7.0.0 Schrödinger, n.d.) (shown in Figure 2). Features were selected based on 
key interactions to TLR4 obtained from X-ray structure (Park et al., 2009), five features for LPS 
and eight features for MD-2 loop were determined. Independent screens were performed for both 
pharmacophores, and compounds were selected to match at least four of the features. 
Docking-based virtual screening was conducted using Glide SP [Schrödinger] with standard 
parameters. The grid generation for the docking-based screens was based on an area of 10 Å around 
key amino acids in LPS binding site or in MD-2 loop site in TLR4 (shown in Figure 3). The 
complete library (140 000 compounds) was docked to both the LPS and MD-2 binding sites, to 
mimic the binding of the co-ligand or the helper protein. Compounds were ranked based on their 
docking scores (GlideXP). 
2.1 Experimental screening using a gene-reporter assay 
The primary experimental screen was conducted for the 1 000 compounds that could be physically 
obtained following the five virtual screens. Compounds were obtained through acoustic dispensing 
and tested in 384-well plate format. The HEK-Blue™-hTLR4 (cat. no. hkb-htlr4, InvivoGen) cell 
line, co-expressing the human MD-2 and CD14, was used and the level of TLR4 activation was 
determined by measuring the level of secreted embryonic alkaline phosphatase (SEAP) activity in 
         
the cell culture medium. In the HEK-Blue™-hTLR4 cell line, the SEAP reporter gene is 
downstream of NF-κB and AP1 binding sites. Cells were cultivated at 37°C in 5% CO2 in an air‐
ventilated humidified incubator, in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 0.2% Normocin™ and 0.4% HEKBlue selection antibiotics. 
For testing, the cells were plated in DMEM supplemented with 0.5% FBS and antibiotics using a 
BRAD (BioTek MultiFlo FX with Random Access Dispensing technology) dispenser. After an 
overnight incubation, the compounds were added from matrix plates (BioMek FXp), two replica 
wells for each compound, at 5 µM concentration, and incubated for 30 min before LPS was added 
(sonic dispension with ECHO). TAK-242 was used as a positive control, to show full inhibition of 
TLR4 activation. 1 ng/mL LPS-EK Ultrapure (cat. code tlrl-peklps, InvivoGen) was used for 
submaximal activation of TLR4 (signal/background S/B=5.0, Z’=0.66; 10 ng/mL LPS producing 
S/B=8.8). On the next day NovaBright™ (cat. no. N10578, NovaBright Phospha-Light EXP Assay 
Kit for SEAP, Invitrogen) reagent buffer was added to assay plates (nonplacental alkaline 
phosphatase activity inhibition) (BRAD) and followed by medium addition (BioMek FXp). Assay 
plates were sealed, incubated for 5 min, at 65 °C, and equilibrated to room temperature. 
NovaBright™ assay reagent was added (BRAD) and plates incubated for 20 min at room 
temperature. The SEAP signal was measured as a TLR4 activation signal for 0.1-1 s/well 
(luminescence, Pherastar FS). To measure cytotoxicity, ATP was measured from the cells using the 
CellTiter-Glo® (cat. no. G7570, Promega) reagent according to manufacturer’s protocol 
(luminescence, Pherastar FS). 
2.2 Validation of positive hits 
Compounds were repurchased from independent suppliers (Biovision:  vatalanib   (N-(4-
chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine), mitoxantrone, pixantrone; Abcam: 
banoxantrone (2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-
dioxoanthracen-1-yl]amino]-N,N-dimethylethanamine oxide), benazepril (2-[(3S)-3-[[(2S)-1-
ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic 
acid), salicin ((2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-
triol); Carbosynth: mitoxantrone (2-hydroxyethyl)piperazine; ChemBridge: CAS610281-22-6 (1-(4-
chloro-2-methylphenoxy)-3-[(1-phenylethyl)amino]-2-propanol); Specs: CAS900453-15-8 (7-
benzyl-2-[[(4-chlorophenyl)amino]methyl]-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-
d]pyrimidin-4(3H)-one); Akos: CAS1021989-35-4 (N-(9-ethyl-9H-carbazol-3-yl)-N
2
-
methylglycinamide), SigmaAldrich: (-)-etoposide ((5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-
7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-
3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one), 
InvivoGen: TAK-242) (Figure 4 and 1). The identity of compounds was independently verified 
with ultra-performance liquid chromatography – high resolution mass spectrometry (Waters 
Acquity® UPLC system attached to Acquity PDA detector and Waters Synapt G2 HDMS mass 
spectrometer) or nuclear magnetic resonance (NMR) spectroscopy (Bruker Ascend 400 
spectrometer). Validation of the hits from the first experimental screen was done with a dose-
response analysis. HEK-Blue™-hTLR4 cells were cultivated and plated as previously. 9000 
cells/well were plated on clear 96-well plates (cat. no. 655180, CELLSTAR®, Greiner Bio-One), 
leaving the outer wells cell-free and filled with sterile water to minimize evaporation. After 
overnight incubation, the compounds were added in DMEM supplemented with 0.5% FBS with 
final concentrations of 5 µM, 1 µM and 500 nM, and incubated for 30 min prior to stimulation with 
LPS or phorbol 12-myristate 13-acetate (PMA, a TLR4-independent NF-κB activator, cat. no. tlrl-
pma, InvivoGen). After 22 hours of incubation, the media was collected and added to a 96-well 
opaque plate (cat. no. 6005290, Optiplate-96, PerkinElmer). Novabright™ assay buffer was added 
and incubated for 5 min, at 65 °C and equilibrated to room temperature as previously. Novabright™ 
reagent buffer was added and incubated for 20 min at room temperature in a dark condition, and the 
         
SEAP-signal was detected (FLUOstar OPTIMA, BMG Labtech). Cell viability was controlled with 
the CellTiter-Glo® luminescent cell viability assay as reported above (FLUOstar OPTIMA, BMG 
Labtech). 
2.3 TNFα detection 
To further investigate the biological effect of the compounds, an ELISA-based (cat. no. 88-7324-22, 
Invitrogen) detection of TNFα secreted from neonatal mouse microglia culture was used. Brains 
were dissected from P1-P3 NMRI mouse pups, meninges were removed, and brains sliced and 
washed with Hanks’s balanced salt solution (HBSS). Tissue pieces were incubated for approx. 15 
min, at 37 °C with 1 mg/mL trypsin in HBSS, and treated with DNaseI (20-40 µg/mL) in 10% FBS 
+ HBSS. Pieces were washed again with HBSS and triturated mechanically. Undissociated tissue 
was collected by spinning (400  g, 5 min), followed by another round of mechanical dissociation 
of the pellet. Dissociated cells were plated in DMEM:F12 (Nutrient Mixture F-12) supplemented 
with 15% FBS and 0.5% Primocin
TM
 in T-75 cell culture flasks (cat. no. 658175, CELLSTAR®, 
Greiner Bio-One), an cultivated at 37°C in 5% CO2 in an air‐ventilated humidified incubator. The 
concentration of FBS was reduced to 10% after 3 d in culture. At least 8 d later, when the cell layer 
was confluent, microglia were isolated by shaking the plate for 2 h at 37 °C, 190 rpm. Depending 
on the yield of microglia isolation, 15 000 to 30 000 cells were seeded on clear 48-well plates (ct. 
no. 677180, CELLSTAR®, Greiner Bio-One) (coated with 0.1 mg/mL poly-L-ornithine). Microglia 
cells were stimulated by the antagonist TAK-242 (a positive control) and by mitoxantrone, 
pixantrone and mitoxantrone (2-hydroxyethyl)piperazine 30 min prior the stimulation with LPS (1 
ng/mL). For the control wells dimethyl sulfoxide (DMSO) (0.25 ‰) was added, according to the 
final concentration of DMSO in stimulated wells. After 23 h the media was collected and TNFα 
levels detected with mouse TNF α ELISA Ready-SET-Go® (cat. no. 88-7324-22, Invitrogen) 
according to a manufacturer’s protocol and measured with Wallac 1420 Victor through absorbance 
(PerkinElmer). Any effects on cell viability were determined from ATP levels measured with the 
CellTiter-Glo® as reported above, using Wallac 1420 Victor plate reader. 
2.4 Radioligand binding 
To demonstrate direct binding to TLR4, the specific binding of tritium-labeled mitoxantrone 
(Hartmann Analytic GmbH, Braunschweig, Germany) to TLR4-expressing membranes from HEK-
Blue™-hTLR4 cell line was investigated. Cells were collected, spinned and frozen down as a pellet 
at least for 24 h in -80 °C. On the next day, the cells were thawed, suspended in experiment buffer 
(50 mM phosphate buffer + 1 mM EDTA), and homogenized on ice with ultrasound liquid 
processors sonicator (Misonix XL-2000) for 5  6 s. Nuclei and cell debris were removed by 
spinning (1000  g, 10 min, 4 °C), the supernatant was collected and the pellet was resuspended in 
experiment buffer. The homogenization and spinning were repeated for resuspension, and 
supernatant collected. The fraction was treated with 10 g/mL DNaseI and 0.5 mM MgCl2 at room 
temperature, and once more spinned (10 000  g, 5 min, 4 °C) to remove mitochondrial DNA. The 
membrane fraction was collected by ultracentrifuge (100 000  g, 25 min, 4 °C), and suspended into 
experiment buffer + 0.32 M saccharose. The fractions were stored in -80 °C. Protein amount was 
measured by Bradford method (Bradford Reagent, Sigma-Aldrich) according to manufacturer’s 
protocol with bovine serum albumin (BSA) as standard. Five to ten µg protein was used per well 
diluted in experiment buffer + 1% BSA. Filter-bottomed 96-well MultiScreen HTS plates 
(Millipore) were used. LPS-RS standard (cat. code tlrl-rslps, InvivoGen), lipopolysaccharide from 
the photosynthetic bacterium Rhodobacter sphaeroides was used as a cold ligand, control for 
assessing non-specific binding. Excessive amount of LPS-RS (100 ng/mL) was used in order to 
saturate TLR4 receptors, and thus prevent radio-ligand binding on these receptors. The cold-ligand 
or an equal volume of experiment buffer was added to wells of unspecific binding or total binding, 
         
respectively, prior loading the membrane fraction samples. After loading the membrane fraction 
samples, the radio-ligand was added to all wells, and plates were incubated for 2 h at room 
temperature to reach equilibrium. Plates were washed with cold PBS to remove unbound radio-
ligand. Liquid scintillation cocktail Optiphase HiSafe 3 (PerkinElmer) was added, and radioactivity 
was measured with liquid scintillation counting (CPM) (Wallac Microbeta Trilux microplate liquid 
scintillation counter, PerkinElmer). Specific binding was determined by subtracting the non-specific 
binding from total binding. A second method for determining non-specific binding was also tested 
using membrane fraction from HEK-293T cells that are not expressing TLR4s, and the results 
found to be highly concordant (supplementary material, Figure S1). 
2.5 Statistical analysis 
Biological experiments were conducted in triplicate (TNFα detection and binding) or in 
quadruplicate (SEAP), and using several batches of cells. Data were normalized to maximum before 
averaging, and presented with mean ± S.E.M (TNFα detection and binding) or mean ± ST.DEV 
(SEAP). Data were analyzed with Prism 5 and Prism 7 (GraphPad Software Inc. La Jolla, CA, 
USA), and significance was defined with 2-way ANOVA, followed by Tukey’s (SEAP) or 
Fischer’s LSD (TNFα) post hoc tests. Significance is marked as follows: ns (not significant; 
P > 0.05), * P < 0.05, * * P < 0.01, *** P < 0.001, **** P < 0.0001. Data were visualized with Prism 
5, Prism 7, Pymol and Discovery Studio.  
         
3 Results 
3.1 Virtual screening 
Five independent lists of 200 compounds were constructed totaling 1 000 compounds that could be 
physically obtained. Controls that could be used to calculate enrichment factors were lacking in 
virtual screens, since the screens were conducted in near absence of known small-molecule TLR4 
antagonists. Thus multiple computational methods were used and combined, with the hope for one 
to be superior to the others. Since very few hits were obtained after primary experimental screen, it 
does not make sense to actually compare the virtual screening methods in retrospect. 
As a result of the virtual screens, for similarity search, more than 200 most similar compounds to 
the β-amino alcohol derivative were obtained (Tanimoto similarity above 0.5). For pharmacophore 
modeling of the MD-2 loop, eight features were defined; and for the pharmacophore modeling of 
LPS, five features were defined, drawn from molecular interactions seen in the X-ray structure 
(Park et al., 2009) (Tables 1 and 2, Figure 2). Compounds were then retrieved to fit hypotheses 
combining four out of eight features (MD-2 site) or four out of five features (LPS site). Features 
(Figure 2, labeled with numbers) are defined in detail in Tables 1 and 2. The features were selected 
to keep enough compounds in the hit lists while including the molecular interactions regarded as 
significant. The active compound identified in this study, mitoxantrone, was originally returned 
from the LPS pharmacophore-based screen. The docking screens were blindly run in the two 
structural areas identified (Figure 3). Since docking screens simply rank the library, they always 
return a populated hit list. 
3.2 Experimental screening using a gene-reporter assay 
The primary screening resulted in a small hit list of 20 compounds showing inhibition of the SEAP 
LPS-induced activation signal superior to 20%, at least in one replica well (Figure 5). The 
screening was conducted in two replica plates, and when limiting the hit criteria as observation in 
both replica wells, the hit list contain only 11 compounds: mitoxantrone (Figure 1), vatalanib, 
benazebril, CAS128113-19-9 (5-[[2-(dimethylamino)ethyl]amino]-8-hydroxy-6H-
[1,2,3]triazolo[4,5,1-d,e]acridin-6-one), (-)-etoposide, gemcitabine (4-amino-1-[(2R,4R,5R)-3,3-
difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one), salicin, CAS1021989-35-4, 
CAS900453-15-8, foscarnet (phosphonoformic acid), and CAS610281-22-6 (Figure 4). Having 
high well-to-well variability when compared to the controls (only DMSO and DMSO + LPS treated 
wells), the data was normalized to the local average, which indeed lowered the variation between 
wells. Controls worked as expected, i.e. the negative control LPS (1 ng/mL) treatment increased the 
signal by 3.9-fold (70% of maximal); whereas the positive control TAK-242 (500 nM) reduced the 
LPS-induction down to 20-25%, i.e. showed full inhibition. Only two compounds from the hit list 
of 11 compounds, mitoxantrone and (-)-etoposide, showed slight cytotoxicity when cell viability 
was controlled with CellTiter-Glo (74.4% and 78.9%, respectively, of control well ATP 
representing 100% viable cells). Mitoxantrone was clearly the strongest inhibitor of the list, as cells 
treated with mitoxantrone (5 µM) were showing only 16.5% of the submaximal signal of LPS-
induced SEAP. 
Mitoxantrone is a polypharmacological immunosuppressive drug that is mostly used for the 
treatment of various cancers (Evison et al., 2016) and MS (English and Aloi, 2015). The main 
limitation of the drug is due to its cardiotoxicity (Pattoneri et al., 2009; Reis-Mendes et al., 2015), 
and therefore less toxic derivatives have been developed, including pixantrone (Hasinoff et al., 
2016) and the mitoxantrone metabolite mitoxantrone (2-hydroxyethyl)piperazine (Reis-Mendes et 
al., 2017). Mitoxantrone is a well-known inhibitor of topoisomerase II (Tewey et al., 1984), but it 
         
also has various other targets (see for a recent review (Evison et al., 2016)). Despite the well-
characterized cardiotoxic mechanism of mitoxantrone, its immunosuppressive mechanism is not 
fully understood. Lowering the levels of inflammatory cytokines is mostly thought to be derived 
from preventing proliferation of macrophages, such as T- and B-cells (Maghzi et al., 2011), as well 
as from preventing the migration of immunocompetent cells (Kopadze et al., 2006). The mechanism 
of pixantrone has been considered to be similar to mitoxantrone (Mazzanti et al., 2005). 
Considering distinctly the best hit, commercially available compounds around the mitoxantrone 
were searched, and three analogues were included to further tests. As a result of the primary screen, 
accounting for the commercial availability of the other hits, 11 compounds were chosen to undergo 
validation: mitoxantrone, banoxantrone, pixantrone, mitoxantrone (2-hydroxyethyl)piperazine, 
vatalanib, benazepril, (-)-etoposide, salicin, CAS1021989-35-4, CAS900453-15-8 and CAS610281-
22-6. Due to commercial unavailability or unwanted properties CAS-128113-19-9, foscarnet and 
gemcitabine were excluded from the further validation. 
3.3 Validation of positive hits 
After purchasing compounds from individual suppliers, 11 compounds were retested at three 
different concentrations (0.5 µM, 1 µM, 5 µM). As a result, only one compound from the primary 
experimental screen, mitoxantrone, showed significant dose-response-dependent inhibition of TLR4 
activation signal (2-way ANOVA, P ≤ 0.0001) (Figure 6a). Mitoxantrone lowered the SEAP levels 
to 65% ± 1.7% at 1 µM. In addition, the analogues tested, pixantrone (Figure 6a) and mitoxantrone 
(2-hydroxyethyl)piperazine (Figure 6a), showed weaker concentration-dependent inhibition, 
lowering SEAP levels to 71% ± 3.4%; 72% ± 1.8%, respectively, at the same concentration (Figure 
6a). Together, the activity of the analogues supports the activity of mitoxantrone. Mitoxantrone and 
analogues showed significant cytotoxicity (2-way ANOVA, P ≤ 0.0001), at 5 µM, showing approx. 
70% of control well ATP; but only mitoxantrone was significantly cytotoxic at lower 
concentrations, showing approx. 79% of control well ATP (Figure 6b). Next, we wanted to exclude 
the possibility that mitoxantrone and its derivatives reduce SEAP levels in a TLR4-independent 
manner (e.g. by interfering with other events either downstream or upstream of the reporter gene 
transcription (Chang et al., 2005)). For that purpose we assessed the effect of these compounds on 
reporter gene activation by PMA, a specific protein kinase C (PKC) activator (Takeuchi et al., 
1992). Mitoxantrone and derivatives showed a significant effect (2-way ANOVA, P ≤ 0.0001) on 
PMA-induced activation of the SEAP reporter gene, but not a typical dose-response. Surprisingly, 
TLR4 bound antagonist TAK-242 (500 nM) also had a significant lowering effect on PMA-induced 
reporter activation (2-way ANOVA, P ≤ 0.0001) (Figure 6c). Thus, the effect of compounds was 
compared also to the effect of TAK-242. Only the highest tested concentrations of mitoxantrone 
and pixantrone (5 µM) had a stronger effect on PMA-induced reporter activation than TAK-242 
(Tukey’s test, P ≤ 0.0001; P ≤ 0.05; respectively), an effect likely caused by the cytotoxicity of 
these compounds at higher concentration (Figure 6d). 
3.4 TNFα detection 
A concentration-dependent effect of mitoxantrone, pixantrone and mitoxantrone (2-
hydroxyethyl)piperazine on LPS-stimulated mice microglia was tested to investigate the effect of 
the compounds in the production of proinflammatory cytokines. A clear concentration-dependent 
and significant (2-way ANOVA, P ≤ 0.0001, followed by Fisher’s LSD analysis) effect on TNFα 
production was seen with pixantrone and mitoxantrone (2-hydroxyethyl)piperazine (Figure 7). At 5 
µM concentration, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine reduced significantly 
(Fischer’s LSD, P  ≤ 0.0001) the level of TNFα to 46% ± 14.9% and 48% ± 10.1%, respectively, 
from only LPS-treated cells. A significant effect (Fischer’s LSD, P  ≤ 0.01) was seen also at 1 µM, 
         
where compounds lowered TNFα levels to 67% (± 11.4% [pixantrone]; ± 9% [mitoxantrone (2-
hydroxyethyl)piperazine]). The positive control TAK-242 (500nM) lowered TNFα levels to 34.3% 
± 0.1%. However, significant cytotoxicity (2-way ANOVA, P ≤ 0.05) was observed. At the highest 
concentration (5 µM) of pixantrone and mitoxantrone (2-hydroxyethyl)piperazine lowered the ATP 
levels to ~79% of ATP of LPS-treated cells, however the effect was significant (Fischer’s LSD, P ≤ 
0.05) only in pixantrone-treated cells. Mitoxantrone showed high cytotoxicity on microglia (500 nM 
lowered ATP levels to 14.6% ± 2.3%; N=2), and thus TNFα levels could not be analyzed 
(supplementary material, Figure S2). At low toxic concentration (50 nM), mitoxantrone reduced the 
TNFα production from only LPS-treated cells around the same range than its derivatives (84.5% ± 
20.8%; N=2; supplementary material, Figure S3). 
3.5 Radioligand binding 
To demonstrate the action of mitoxantrone through the TLR4 receptor, we measured the binding of 
[
3
H]mitoxantrone to TLR4-expressing membrane fraction from HEK-Blue™-hTLR4 cells in the 
presence or absence of a known TLR4 antagonist LPS-RS. The presence of LPS-RS (at final 
concentration of 100 ng/mL) reduced the binding of [
3
H]mitoxantrone to membrane fraction of 
HEK-Blue™-hTLR4 cells, but did not have an effect on [
3
H]mitoxantrone binding to membrane 
fraction of HEK-293T cells that do not express TLR4 (supplementary material, Figure S4). 
At lower concentrations (≤ 125 nM) the concentration-response curve seems to reach the saturation, 
however at higher concentrations the response ascends steeply (Figure 8). This is likely caused by 
high non-specific binding, especially seen at high concentrations (supplementary material, Figure 
S5). However, the LPS-RS-sensitive TLR4-specific binding was observed concentration-
dependently and robustly in several repeats at many concentrations of [
3
H]mitoxantrone (Figure 8). 
At higher concentrations, non-specific binding partially occluded the results: high variation in 
binding experiments was observed and saturation was not distinctly reached, most likely due to high 
non-specific binding, binding affinity values could not be determined reliably. The fact that specific 
binding was observed, when the cold ligand LPS-RS was present, may suggest that 
[
3
H]mitoxantrone binds to the same site as lipopolysaccharides.  
         
4  Discussion 
Taken together, results of this study suggest that mitoxantrone and its derivatives pixantrone and 
mitoxantrone (2-hydroxyethyl)piperazine inhibit the TLR4 activation signal by binding directly to 
TLR4 and most likely at the same binding site as LPS. This data adds to the emerging number of 
novel small molecule inhibitors of TLR4 that have been reported recently (see e.g. (Marshall et al., 
2016; Peri and Calabrese, 2014; Wang et al., 2016; Zaffaroni and Peri, 2018). These various TLR4 
ligands are from synthetic origin are such as neoseptins and Ugi compounds, and several are lipid 
mimetics of the glycolipid part of LPS; or from natural sources such as curcumin, cinnamaldehyde 
and glycyrrhizin. 
The inhibitory effect of mitoxantrone, pixantrone, and mitoxantrone (2-hydroxyethyl)piperazine on 
TLR4 activation signal in SEAP-reporter assay was detected. The effect was significant and 
concentration-dependent, and not mediated through cytotoxicity (controlled by ATP counts) at 
lower concentrations. However, an issue with reporter assays is often having the reporter far 
downstream from the target, thus the mechanism of action may be indirect from the target and not 
occurring through target activation. Thus, a possible TLR4-independent effect in SEAP-reporter 
assay was investigated with PMA-induction of NF-κB. A significant, but not distinctly 
concentration-dependent, effect on PMA-induction was observed, indicating that the reducing effect 
of the compounds on LPS-driven activation signal is likely not a TLR4-independent effect on the 
NF-κB activation pathway.  Moreover, the effect of mitoxantrone and derivatives was not 
significantly higher than the effect of the control antagonist TAK-242 on PMA-induced TLR4 
activation at lower concentrations (≤ 1 µM). 
Further, [
3
H]mitoxantrone binds to the membrane fraction of TLR4-expressing cells. However, it is 
still possible that the compounds would bind to membrane-anchored adaptor proteins in the 
membrane fraction and not to TLR4. In addition, a large variation in bound molecule per milligram 
of protein between experiments, affected the robustness of the binding results. However, all the 
experiments showed concentration-dependent specific binding when controlled with LPS-RS (or 
with HEK-293T membrane fraction). Being able to block [
3
H]mitoxantrone binding sites with LPS-
RS suggests a common binding site, likely in TLR4. However, to definitely prove specificity, a 
counter screen with other TLRs would be needed, which is beyond the scope of this study. 
There is previous evidence, that mitoxantrone is actually rather indirect promoter of activation of 
NF-κB through topoisomerase II poisoning, in leukemia HL60 cells (but not HL60/MX2 cells that 
do not express topoisomerase II), and NF-κB is also known as one of the apoptosis regulators 
(Boland et al., 2000). There is also opposite evidence of mitoxantrone being potent inhibitor of PKC 
(Takeuchi et al., 1992), with 8.5 µM IC50 value in HL60 cells, which inhibits further NF-κB. The 
inhibition was mostly detected in cytosolic fraction. Cytosolic fraction was ruled out in our binding 
measurements, indicating that mechanisms of inhibition are not only direct to PKC, but include 
TLR4-dependent activation too. This could partly, in addition to cytotoxicity, also explain 
significant inhibition of mitoxantrone and analogues (5 µM) on PMA induction. 
An immunosuppressive/modulatory mechanism of mitoxantrone has been described in the 
periphery, showing the inhibitory effect on proliferation and migration of macrophages (Kopadze et 
al., 2006; Maghzi et al., 2011), as well as showing a cytotoxic and immunomodulatory effect on 
CNS-specific macrophages (microglia) (Li et al., 2012). However, no protein molecular target has 
been described before this study. The data presented here indicate that the mechanism could be 
TLR4-mediated. Consistent with previous data on mitoxantrone (Fidler et al., 1986; Neuhaus et al., 
2001) and pixantrone (Mazzanti et al., 2005), a concentration-dependent and significant reduction 
         
of TNFα is here detected and reported to the best of our knowledge for the first time in mouse 
microglia using pixantrone and mitoxantrone (2-hydroxyethyl)piperazine-treated cells. 
5 Conclusion 
Toll-like receptor 4 is a very challenging protein for in silico screens due to its large size and 
location at an interaction hub as well as to the presence of multiple potential binding sites. Our in 
vitro tests lead to a very small hit rate, with only one hit eventually, which is much lower than for 
example G protein-coupled transporters or ABC transporters (Turku et al., 2016; Wissel et al., 
2015). The absence of a well-identified binding pocket as well as the scarcity of the known ligands 
to be used as controls has certainly significantly hampered the virtual screens.  
Nonetheless, this study suggests new potential mechanisms of action for mitoxantrone by implying 
that its immunosuppressive effect is TLR4-dependent. Due to the fact that mitoxantrone and its 
derivatives are promiscuous drugs, it is difficult to evaluate their therapeutic potential when 
targeting TLR4. In addition, intravenously administered mitoxantrone or analogues do not cross the 
blood-brain-barrier prominently. Thus, TLR4-mediated effects in the CNS are unlikely unless the 
blood-brain barrier is disrupted which may be the case e.g. in MS (Ergin et al., 2012). Regardless of 
such, the scaffold of mitoxantrone could be useful in the design of novel TLR4 inhibitors. 
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Figure Captions 
Figure 1. Chemical structures of  the antineoplastic agents mitoxantrone, pixantrone, and 
mitoxantrone (2-hydroxyethyl)piperazine, TAK-242 and a racemic β-amino alcohol derivative 
(Bevan et al., 2010) used in similarity search.  
 
 
Figure 2. Pharmacophore features based on (a) MD-2 loop, from Gly-97 to Leu-108, and (b) LPS 
binding modes. Green = hydrogen bond acceptor, magenta = hydrogen bond donor, and blue = ionic 




         
Figure 3. (a) Extracellular domain of human TLR4 dimer (green), in complex with MD-2 helper 
protein (magenta) and co-ligand lipopolysaccharide (cyan) (b) MD-2 loop F126 (magenta) binding 
site and interactions with TLR4 (green). (c) LPS (cyan) binding site and key interactions of 
glycolipid part with TLR4 (green), and the second TLR4 monomer (blue*).  
 
 
Figure 4. Chemical structures of banoxantrone, vatalanib, benazepril, (-)-etoposide, salicin, CAS 





         
 
Figure 5. (a) Results of the experimental screening of 1000 compounds, replica wells plotted to 
proprietary axis. Compounds showing > 20% inhibition of full-activation of LPS induction in both 
replica wells are circled with red. (b) Twenty best hits of the first round of experimental screening, 
showing inhibition of LPS-induced activation signal > 20% at least in one replica well. a) 
Mitoxantrone, b) vatalanib, c) benazebril, d) CAS128113-19-9, e) (-)-etoposide, f) gemcitabine, g) 
salicin, h) CAS1021989-35-4, i) CAS900453-15-8, j) foscarnet, k) CAS610281-22-6 inhibited LPS-
induced activation signal ≥ 20% (average). Compounds l-t were not added to further validation, 
because of their low inhibition potential (average < 20%). Data normalized to local average. 
 
 
Figure 6. Concentration-response on SEAP and cytotoxicity of mitoxantrone, pixantrone and 
mitoxantrone (2-hydroxyethyl)piperazine. Data normalized to the signal of LPS/PMA treated cells 
(100%; bar not shown). (a) Inhibitory effect on LPS (0.2 ng/mL) –induced TLR4 activation signal 
(SEAP) (P ≤ 0.0001 for all, except for 0.5 µM pixantrone P ≤ 0,01, compared with only LPS-treated 
cells, presented above each bar). Significant difference within concentrations is shown only in 
adjacent conditions (bracket). (b) Cytotoxicity, significance compared with LPS-treated cells. (c) 
Inhibitory effect on PMA (10 ng/mL) -induced activation of TLR4. Significant difference compared 
with PMA-treated cells, stars above bars; comparison with TAK-242 (500 nM), bracket. (d) 
Cytotoxicity compared with PMA-treated cells. Significance assessed by using Tukey’s test, all data 
are expressed as mean ± SD, N = 4.  




         
 
Figure 7. Concentration-response and cytotoxicity of pixantrone and mitoxantrone (2-
hydroxyethyl)piperazine on LPS-stimulated mice microglia. Data normalized to the signal of LPS-
treated cells (100%; bar not shown). (a) Inhibitory effect on TNFα production. Significant 
difference, compared to only LPS-treated cells, presented above bars. Significant difference within 
groups showed only in adjacent bars (bracket). (b) Cytotoxicity, significance comparison to LPS-
treated cells. Significance assessed by using Fisher’s LSD analysis, data are expressed as mean ± 





H]Mitoxantrone binds specifically to TLR4-expressing membrane fractions, controlled 
with the known TLR4 antagonist LPS-RS. Specific binding to TLR4 was calculated by subtracting 
non-specific binding (TLR4-expressing membranes blocked with LPS-RS) from total binding 
(TLR4-expressing membranes alone). (a) A graph representing all concentrations, (b) represents a 
zoom of (a) and shows concentration-dependency also at lower concentrations (≤ 125 nM). Data are 




         
Tables 
Table 1. Molecular features of MD-2 loop – TLR4 interactions that were used in the 
pharmacophore-based virtual screen. HB = hydrogen bond. 
Feature type MD-2 Functional group TLR4 
1. HB donor Ser-98 -OH side chain hydroxyl Arg-289 
2. Ionic Asp-99 -COOH side chain carboxylate Arg-289 
3. HB acceptor Asp-99 -C=O- Asp-100 main chain carbonyl Arg-234 
4. HB acceptor / 
Ionic 
Asp-101 -COOH side chain carboxylate Ser-317, Arg-264 
5. HB acceptor Asp-101 -C=O- Tyr-102 main chain carbonyl Arg-264 





Ser-103 -OH side chain hydroxyl Asn-265, Glu-266 
8. HB 
acceptor/donor 




Table 2. Molecular features of LPS – TLR4 interactions (the second TLR4 monomer*) that were 
used in the pharmacophore-based virtual screen. HB = hydrogen bond. 
Feature type LPS Atom number in 
PDB 
TLR4 
1. HB acceptor 1-PO4 1011 Lys-341, Lys-362 
2. HB acceptor 4´-PO4 1010 Lys-362, Arg264 
3. HB acceptor C-O-C 1012 Tyr-296 
4. HB acceptor C=O 1006 Arg-264 
5. HB donor R2-OH 1003 Gln-436* 
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